Anaconda Biomed SL raised $56 million for product development and clinical work, including completion of a pivotal investigational device exemption study evaluating its Ana Funnel catheter for stroke. The funding is intended to support safety and performance evidence generation alongside ongoing development. The round underscores continued investment in interventional neurology devices as companies compete to reduce time-to-treatment and improve outcomes in acute stroke settings. For device developers, the focus remains on generating robust trial data that can support regulatory pathways while preparing for broader clinical adoption.